Form 8-K · Current Report · Filed 2026-04-29
AbbVie Reports First-Quarter 2026 Financial Results and Raises Guidance
AbbVie Inc. reported first-quarter 2026 financial results, with net revenues of $15.002 billion, an increase of 12.4% on a reported basis. Diluted EPS was $0.39 on a GAAP basis, a decrease of 45.8%, and $2.65 on an adjusted basis, an increase of 7.7%. The company raised its full-year 2026 adjusted diluted EPS guidance range from $13.96 - $14.16 to $14.08 - $14.28, which includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2026.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001551152-26-000013
- CIK
- 0001551152
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$197.69
Next session
+6.9%
Since filing
+26.9%
Latest close
$250.94
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ABBV insiders reported 11 Form 4 transactions — flat net activity.
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.